Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Receivables - Net: 2009-2024

Historic Receivables - Net for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $11.7 million.

  • Cumberland Pharmaceuticals' Receivables - Net fell 7.78% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 7.78%. This contributed to the annual value of $11.7 million for FY2024, which is 19.91% up from last year.
  • According to the latest figures from FY2024, Cumberland Pharmaceuticals' Receivables - Net is $11.7 million, which was up 19.91% from $9.8 million recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Receivables - Net high stood at $13.2 million for FY2022, and its period low was $6.9 million during FY2021.
  • In the last 3 years, Cumberland Pharmaceuticals' Receivables - Net had a median value of $11.7 million in 2024 and averaged $11.5 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Receivables - Net tumbled by 44.44% in 2021, and later soared by 91.41% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Receivables - Net (Yearly) stood at $12.4 million in 2020, then crashed by 44.44% to $6.9 million in 2021, then soared by 91.41% to $13.2 million in 2022, then dropped by 25.87% to $9.8 million in 2023, then increased by 19.91% to $11.7 million in 2024.